2017 NCCN Case Manager and Medical Director Program: Updates in the Diagnosis and Treatment of Lung Cancer

November 7, 2017

Join Gregory A. Otterson, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute as he presents Updates in the Diagnosis and Treatment of Lung Cancer as part of the NCCN 2017 Oncology Case Manager and Medical Director Program Webinar Series.

Many therapeutic options exist for patients with non-small cell lung cancer (NSCLC), but the different options can seem overwhelming for patients who need educating about the options before making decisions. The NCCN Guidelines for Patients® are a valuable resource for educating patients about lung cancer. Case managers and other healthcare professionals involved in care planning and coordination need to be knowledgeable about all the treatment options and biomarker testing recommendations for patients with NSCLC and need to be aware that recommendations are rapidly changing so they can discuss the risks, benefits, and appropriateness with each patient. Healthcare professionals also need to be aware of new NCCN tools for quickly and accurately educating patients about the different therapeutic options based on efficacy, safety, quality and consistency of the evidence, and affordability (see the NCCN Clinical Practice Guidelines in Oncology® with NCCN Evidence Blocks™ for Non-Small Cell Lung Cancer). Informed shared decision making can enable patients to receive high-quality and cost-effective care that maximizes their survival while taking into account their values and preferences.

Target Audience

This program is designed to meet the educational needs of case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.

Learning Objectives

Following this activity, participants should be able to:

  • Educate patients by providing a broad overview of lung cancer.
  • Discuss appropriate biomarker tests for patients with non-small cell lung cancer (NSCLC).
  • Describe the different types of immunotherapy and targeted therapy for patients with metastatic NSCLC.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Genentech
  • Genomic Health, Inc.
  • Olympus Corporation of the Americas
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from AbbVie and Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 CCM clock hours
  • 1.25 Participation
Course opens: 
09/05/2017
Course expires: 
01/05/2018
Event starts: 
11/07/2017 - 1:00pm
Event ends: 
11/07/2017 - 2:15pm
Cost:
$0.00

Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center -
James Cancer Hospital and Solove Research Institute

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses the following relevant financial relationships:
Gregory A. Otterson, MD
Amgen: Scientific Advisor
Celgene Corporation: Scientific Advisor
Genentech, Inc. : Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Melissa Esplen; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (until 10/30/17)

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Miranda Hughes, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category I credits for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.25 contact hours.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. This course is approved for 1.25 CE contact hours. Activity Code: I00028896; Approval #: 170003902

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: 0836-0000-17-110-L01-P

Available Credit

  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 CCM clock hours
  • 1.25 Participation

Accreditation Period

Course opens: 
09/05/2017
Course expires: 
01/05/2018

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing